Literature DB >> 28108512

Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers.

Lisa Choy1, Thijs J Hagenbeek1, Margaret Solon2, Dorothy French2, David Finkle3, Amy Shelton1, Rayna Venook3, Matthew J Brauer4, Christian W Siebel5.   

Abstract

Notch ligands signal through one of four receptors on neighboring cells to mediate cell-cell communication and control cell fate, proliferation, and survival. Although aberrant Notch activation has been implicated in numerous malignancies, including breast cancer, the importance of individual receptors in distinct breast cancer subtypes and the mechanisms of receptor activation remain unclear. Using a novel antibody to detect active NOTCH3, we report here that NOTCH3 signals constitutively in a panel of basal breast cancer cell lines and in more than one third of basal tumors. Selective inhibition of individual ligands revealed that this signal does not require canonical ligand induction. A NOTCH3 antagonist antibody inhibited growth of basal lines, whereas a NOTCH3 agonist antibody enhanced the transformed phenotype in vitro and in tumor xenografts. Transcriptomic analyses generated a Notch gene signature that included Notch pathway components, the oncogene c-Myc, and the mammary stem cell regulator Id4 This signature drove clustering of breast cancer cell lines and tumors into the common subtypes and correlated with the basal classification. Our results highlight an unexpected ligand-independent induction mechanism and suggest that constitutive NOTCH3 signaling can drive an oncogenic program in a subset of basal breast cancers. Cancer Res; 77(6); 1439-52. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28108512     DOI: 10.1158/0008-5472.CAN-16-1022

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

Review 2.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

3.  Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques.

Authors:  Jelena Petrovic; Yeqiao Zhou; Maria Fasolino; Naomi Goldman; Gregory W Schwartz; Maxwell R Mumbach; Son C Nguyen; Kelly S Rome; Yogev Sela; Zachary Zapataro; Stephen C Blacklow; Michael J Kruhlak; Junwei Shi; Jon C Aster; Eric F Joyce; Shawn C Little; Golnaz Vahedi; Warren S Pear; Robert B Faryabi
Journal:  Mol Cell       Date:  2019-02-07       Impact factor: 17.970

4.  An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice.

Authors:  Jungeun Yu; Christian W Siebel; Lauren Schilling; Ernesto Canalis
Journal:  J Cell Physiol       Date:  2019-06-12       Impact factor: 6.384

Review 5.  Targeting Notch in oncology: the path forward.

Authors:  Samarpan Majumder; Judy S Crabtree; Todd E Golde; Lisa M Minter; Barbara A Osborne; Lucio Miele
Journal:  Nat Rev Drug Discov       Date:  2020-12-08       Impact factor: 84.694

6.  Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.

Authors:  Emilie Bousquet Mur; Sara Bernardo; Laura Papon; Maicol Mancini; Eric Fabbrizio; Marion Goussard; Irene Ferrer; Anais Giry; Xavier Quantin; Jean-Louis Pujol; Olivier Calvayrac; Herwig P Moll; Yaël Glasson; Nelly Pirot; Andrei Turtoi; Marta Cañamero; Kwok-Kin Wong; Yosef Yarden; Emilio Casanova; Jean-Charles Soria; Jacques Colinge; Christian W Siebel; Julien Mazieres; Gilles Favre; Luis Paz-Ares; Antonio Maraver
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

7.  IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.

Authors:  Dong Wang; Jiahui Xu; Bingjie Liu; Xueyan He; Lei Zhou; Xin Hu; Feng Qiao; Anli Zhang; Xiaojun Xu; Huafeng Zhang; Max S Wicha; Lixing Zhang; Zhi-Ming Shao; Suling Liu
Journal:  Cell Death Differ       Date:  2017-10-13       Impact factor: 15.828

8.  NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells.

Authors:  Kenneth G Geles; Yijie Gao; Andreas Giannakou; Latha Sridharan; Ting-Ting Yamin; Jing Zhang; Riyez Karim; Joel Bard; Nicole Piche-Nicholas; Manoj Charati; Andreas Maderna; Judy Lucas; Jonathon Golas; Magali Guffroy; Steven Pirie-Shepherd; Marc Roy; Jessie Qian; Tania Franks; Wenyan Zhong; Christopher J O'Donnell; Lioudmila Tchistiakova; Hans-Peter Gerber; Puja Sapra
Journal:  Cell Rep Med       Date:  2021-05-18

Review 9.  Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.

Authors:  Frederick Allen; Ivan Maillard
Journal:  Front Cell Dev Biol       Date:  2021-05-28

Review 10.  Notch Signalling in Breast Development and Cancer.

Authors:  Abigail Edwards; Keith Brennan
Journal:  Front Cell Dev Biol       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.